Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9328436 | 0.86 | GABRR1 (0.48) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL27970840 | 0.80 | CYP1A2 (0.44) | TDP1GABRR1CYP1A2ACE2FFAR3 | |
| SCHEMBL15305187 | 0.80 | CYP1A2 (0.62) | TDP1GABRR1CYP1A2ACE2FFAR3 | |
| SCHEMBL6905507 | 0.79 | CYP2C19 (0.46) | TDP1GABRR1CYP1A2FOLH1NAALAD2 | |
| Propionic Acid SCHEMBL28729406 | 0.79 | FFAR3 (0.53) | TDP1GABRR1CYP1A2ACE2FFAR3 | |
| SCHEMBL18052197 | 0.79 | GABRR1 (0.54) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL12672821 | 0.79 | TDP1 (0.45) | TDP1FFAR3 | |
| SCHEMBL1177351 | 0.79 | GABRR1 (0.54) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL13880377 | 0.79 | TDP1 (0.45) | TDP1FFAR3 | |
| SCHEMBL27597486 | 0.78 | GABRR1 (0.38) | GABRR1CYP1A2ACE2FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4305134-A1 | METHOD OF FRACTIONATING A SHEA EXTRACT | Biosynthis (FR) | 2024-01-17 | — | — | EP | disclosed |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022189678-A1 | METHOD OF FRACTIONATING A SHEA EXTRACT | BIOSYNTHIS (FR) | 2022-09-15 | — | — | WO | disclosed |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-10-07 | — | — | US | disclosed |
| US-8182572-B2 | Slow-release fertilizer and method of making and using same | REGAL CHEMICAL COMPANY (US) | 2012-05-22 | — | — | US | disclosed |
| US-20120103370-A1 | DISHWASHING COMPOSITION | RECKITT BENCKISER FINISH B.V. (NL) | 2012-05-03 | — | — | US | disclosed |
| US-20110209252-A1 | SLOW-RELEASE FERTILIZER AND METHOD OF MAKING AND USING SAME | REGAL CHEMICAL COMPANY | 2011-08-25 | — | — | US | disclosed |
| US-20110207647-A1 | COMPOSITION | RECKITT BENCKISER N.V. (NL) | 2011-08-25 | — | — | US | disclosed |
| US-5081145-A | Contractile prostaglandin antagonists | MERCK FROSST CANADA, INC. (CA) | 1992-01-14 | — | — | US | disclosed |
| EP-0166591-B1 | INDOLE-2-ALKANOIC ACIDS AND THEIR USE AS PROSTAGLANDIN ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1989-11-23 | — | — | EP | disclosed |
| US-4837356-A | Process for the preparation of alkyl 4-ketoalkanoates | SHELL OIL COMPANY (US) | 1989-06-06 | — | — | US | disclosed |
| US-4837356-A | Process for the preparation of alkyl 4-ketoalkanoates | SHELL OIL COMPANY (US) | 1989-06-06 | — | — | US | disclosed |
| US-4570021-A | UNSYMMETRICAL KETONES FROM SYMMETRICAL KETONES | SDS BIOTECH CORPORATION (US) | 1986-02-11 | — | — | US | disclosed |
| EP-0166591-A2 | Indole-2-alkanoic acids and their use as prostaglandin antagonists | MERCK FROSST CANADA INC. (CA) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | TDP1 543/4885GABRR1 4175/4885CYP1A2 3159/4885 |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | TDP1 3109/4885GABRR1 1511/4885CYP1A2 265/4885 |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | TDP1 945/4885GABRR1 3129/4885CYP1A2 1034/4885 |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | TDP1 945/4885GABRR1 3129/4885CYP1A2 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.